What it is
BAM-15 is a small molecule — a manufactured chemical, not a peptide (a peptide is a short chain of amino acids). It is a mitochondrial protonophore. That is worth unpacking.
Mitochondria are the tiny structures inside your cells that turn food into usable energy. They do it by pumping charged particles (protons) across an internal membrane, building up a kind of battery, then letting that charge flow back through a turbine that manufactures ATP — adenosine triphosphate, the molecule your cells actually spend as energy. This whole process is called oxidative phosphorylation.
A protonophore lets some of those protons leak back across the membrane without going through the turbine. The charge is still spent, but it comes out as heat instead of as ATP. That is what "uncoupling" means: the burning of fuel is decoupled from the making of ATP. The cell responds by burning more fuel to keep up.
The practical consequence: rather than storing energy as fat, BAM-15 increases energy expenditure by letting mitochondria burn excess fuel as heat. Unlike traditional stimulants and fat-burning compounds, it is reported to do this without increasing heart rate, blood pressure, or body temperature — a cleaner and more targeted metabolic effect.
This is the oral version, taken as a 50 mg pill.
BAM-15 is a small-molecule mitochondrial protonophore — an uncoupler of oxidative phosphorylation. It shuttles protons across the inner mitochondrial membrane, dissipating the proton-motive force so that substrate oxidation proceeds without proportionate ATP synthesis; the freed energy leaves as heat, and respiration accelerates to compensate.
The key comparison is uncoupling without the sympathomimetic signature. BAM-15 is reported to achieve the increase in energy expenditure without raising heart rate, blood pressure, or body temperature, distinguishing it from both stimulant thermogenics and from the classical uncoupler pharmacology whose therapeutic window is defined by hyperthermia.
The practical corollary of that mechanism is the cycle length: 2–4 weeks on, 2–4 weeks off, notably shorter than most protocols on this site.
What it does
It raises the amount of energy your body burns at rest, and pushes cells to use fat for fuel.
Its effects cover three areas. On fat: it improves how the body handles and burns fat, raises resting energy use, and produces weight loss. On blood sugar: it helps regulate blood sugar and increases insulin sensitivity — how well your body responds to its own insulin. On ageing and inflammation: it has senolytic effects and is anti-inflammatory. Senolytic means it inhibits, reverses, or clears out senescent cells — cells that have aged, stopped dividing, and now contribute to ageing and age-related disease.
Because it works by making cells waste fuel as heat, the practical advice follows from the mechanism: dose in the morning, preferably before eating, every day, and keep the cycle short.
Increased resting energy expenditure and enhanced lipid metabolism and fatty-acid oxidation are the primary effects; the glycaemic arm is blood-glucose regulation and improved insulin sensitivity, consistent with the reduction in lipid load on insulin-responsive tissue that uncoupling produces.
Additional claims include senolytic/anti-senescence activity — inhibition, reversal, or clearance of senescent cells — and anti-inflammatory effects.
The key differentiator claimed is haemodynamic neutrality: increased expenditure without tachycardia, hypertension, or hyperthermia, which is the property that separates it from both stimulant thermogenics and the older uncoupler class.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Improves how the body processes and burns fat.Animal or lab only
- Helps regulate blood sugar.Animal or lab only
- Increases insulin sensitivity — how well your body responds to its own insulin.Animal or lab only
- Increases the amount of energy you burn at rest.Animal or lab only
- Weight loss.Animal or lab only
- Senolytic and anti-senescence effects. Senescent cells are aged cells that have stopped dividing and can contribute to ageing and age-related diseases; senolytic effects are processes that inhibit, reverse, or clean out those cells.Anecdotal
- Anti-inflammatory.Animal or lab only
- Taken as a pill — no mixing, no injections.Anecdotal
- Enhanced lipid metabolism and fatty-acid oxidation.Animal or lab only
- Blood-glucose regulation.Animal or lab only
- Increased insulin sensitivity.Animal or lab only
- Increased resting energy expenditure.Animal or lab only
- Weight loss.Animal or lab only
- Senolytic / anti-senescence activity against cells that have exited the cell cycle and contribute to age-related pathology.Anecdotal
- Anti-inflammatory.Animal or lab only
Reconstitution and dosing
One pill (50 mg) per day, every day, for the whole cycle. There is no titration or build-up.
The cycle is short: 2 to 4 weeks on, followed by 2 to 4 weeks off. That is one of the shortest cycles on this site.
Dose in the morning. Taking it on an empty stomach is preferable, though not mandatory.
Fixed dose, no titration: 1 pill (50 mg) daily, 7 days per week, for the duration of the cycle.
Cycle 2–4 weeks with a 2–4 week washout — markedly shorter than the 8–16 week cycles typical elsewhere on this site, an implicit acknowledgement that continuous uncoupling is not intended to be run long.
Morning dosing; fasted preferable but not mandated.
Oral pills — 50 mg per pill
Cycle: 2–4 week cycle followed by 2–4 weeks off · Frequency: Daily (7 days per week); dose in the morning; fasted preferable
| When | Dose | How often |
|---|---|---|
| Whole cycle | 1 pill (50 mg) | once per day, in the morning |
Who should avoid it
- No contraindications have been documented. That is an absence of documentation, not evidence that the compound is safe for everyone.
- Pregnancy, breastfeeding, and use in children have not been addressed.
- Uncoupling compounds work by making the body waste fuel as heat, so anyone with a heart condition, a thyroid condition, or difficulty regulating body temperature has an obvious reason to be careful — even though BAM-15 is specifically reported not to raise heart rate, blood pressure, or body temperature.
- Talk to a doctor before starting, and go through your full medication list with them.
- No contraindication list has been established. Treat that as missing documentation rather than a clean profile.
- Pregnancy, lactation, and paediatric use are unaddressed, as are hepatic and renal function.
- Mechanism-level caution in cardiovascular disease, hyperthyroidism, and thermoregulatory impairment, notwithstanding the reported absence of heart-rate, blood-pressure, or temperature increase.
- No interaction guidance is available for other thermogenics or stimulants.
Side effects
- No side effects have been documented. Again, that means they have not been documented — not that there are none.
- The nearest thing available is a claim about what does not happen: no increase in heart rate, blood pressure, or body temperature.
- The advice to dose in the morning is the usual precaution against sleep disturbance from an energy-raising compound.
- The SLU-PP-332 + BAM-15 combination entry tells you to stay well hydrated and to take electrolytes — sodium, potassium, and magnesium. That advice makes sense for BAM-15 on its own too, though it is not part of the standalone guidance.
- No side-effect data is available.
- The only tolerability statement is negative: no increase in heart rate, blood pressure, or body temperature, in contrast to stimulant thermogenics.
- Morning-only dosing implies a sleep-disturbance concern.
- The SLU-PP-332 + BAM-15 combination entry instructs hydration and sodium/potassium/magnesium repletion, which is a reasonable read-across to standalone BAM-15 given the increased expenditure, though it is carried over from the combination rather than part of the standalone guidance.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
There is no established standalone stacking guidance, but the site sells a single capsule containing SLU-PP-332 and BAM-15 together, and that combination has its own entry here.
Inferred from the existence of the SLU-PP-332 (250 mcg) + BAM-15 (50 mg) combination capsule on this site, rather than from a documented stacking recommendation. Note the blend's BAM-15 content is the same 50 mg as the standalone pill, so the blend is not a reduced-dose version.
The other half of that combination capsule, if you want to run the two separately rather than as a blend. It is also an oral capsule.
The ERR agonist arm run separately: build oxidative capacity with SLU-PP-332, then dissipate the gradient across it with BAM-15. Note the two entries disagree on cycle length — 4–8 weeks for SLU-PP-332 against 2–4 weeks here — so the shorter one governs if they are run together.
Dosing figures have been reviewed and units are recomputed from the stated protocol.